How should procurement teams structure dual-sourcing in the Pharmaceutical Excipients Market without triggering costly requalification?

Qualify both sources concurrently during initial development, not after launch. Filing two suppliers in the original application avoids post-approval change submissions entirely and typically adds only 8–12 weeks to timelines [19]. Read More

What contractual protections matter most when signing a multi-year excipient supply agreement?

Prioritise change-notification clauses requiring 24-month advance notice of any manufacturing site, process or specification change. Add audit rights and guaranteed minimum inventory holdings at the supplier's site [11]. Read More

Do co-processed materials in the Pharmaceutical Excipients Market require separate regulatory review?

No independent approval exists, but co-processed blends need justification of functional performance and safety within the drug application. Compendial monographs now exist for several common combinations, which shortens the argument considerably [20]. Read More

How do inhalation-grade specifications differ from standard oral-grade materials?

Inhalation carriers require tightly controlled particle size distribution, fines content and surface energy — parameters irrelevant for tablets. Only a handful of sites globally hold qualification, which explains persistent supply tightness [28]. Read More

Which due-diligence signals distinguish reliable suppliers in the Pharmaceutical Excipients Market?

Look for IPEC-PQG GMP certification, Certificate of Suitability coverage, and a documented change-control history. Suppliers unable to produce three years of batch-level trend data on critical attributes should be treated cautiously [15]. Read More

Are novel excipients commercially viable given the absence of a standalone approval route?

Viability depends on partnering with a sponsor willing to carry the material through a first application. The FDA pilot programme reduces uncertainty but does not confer approval, so development costs remain sponsor-dependent [20]. Read More

How does nitrosamine risk assessment affect excipient selection today?

Secondary and tertiary amine content in materials now requires documented assessment, and some legacy grades have been reformulated. Buyers should request nitrosamine risk statements as a standard qualification document [15]. Read More

Pharmaceutical Excipients Market (2026 - 2035)

Pharmaceutical Excipients Market Research Report: Size, Share, Trend Analysis By Functionality (Binders, Diluents, Disintegrants, Lubricants, Coatings), By Types (Organic Excipients, Inorganic Excipients, Natural Excipients, Synthetic Excipients), By Formulation Type (Solid Formulations, Liquid Formulations, Semi-Solid Formulations, Novel Drug Delivery Systems), By End Use (Pharmaceutical Companies, Contract Manufacturing Organizations, Research Institutions) and By Regional (North America, Europe, South America, Asia Pacific, Middle East and Africa) - Growth Outlook & Industry - Forecast Till 2035

Forecast Period

2026-2035

CAGR

8.1%

2025 Market Size

USD 11.47 Billion

2035 Market Size

USD 24.88 Billion

Healthcare ● Updated August 2026 Report ID: MRFR/HC/0366-HCR | Pages: 200 | Author: Rahul Gotadki, Nidhi Mandole

Summary Table of Contents Segmentation Methodology Download PDF

1 Market Summary |
1. 1.1 Study Assumptions & Market Definition |
2. 1.2 Scope of the Study |
3. 1.3 Research Methodology
2 Key Report Takeaways |
1. 2.1 By Product Type |
2. 2.2 By Functionality |
3. 2.3 By Formulation |
4. 2.4 By Geography
3 Market Size & Forecast (2021–2035) |
1. 3.1 Historical Market Size (2021–2025) |
2. 3.2 Current & Forecast Market Size (2026–2035) |
3. 3.3 Year-over-Year Growth Analysis
4 Driver Impact Analysis |
1. 4.1 Biologics and Biosimilar Pipeline Expansion |
2. 4.2 Continuous Manufacturing and Process Redesign |
3. 4.3 Emerging-Economy Generic Volume |
4. 4.4 Regulatory Pressure on Impurity and Elemental Profiles
5 Restraints Impact Analysis |
1. 5.1 Requalification Friction |
2. 5.2 Procurement-Driven Price Compression |
3. 5.3 No Standalone Approval Route
6 Opportunity Analysis |
1. 6.1 Oral Peptide and Permeation Enhancement |
2. 6.2 Lipid Systems for Nucleic Acid Therapeutics |
3. 6.3 Emerging-Market Localisation |
4. 6.4 Data and Digital Formulation Services |
5. 6.5 Paediatric and Geriatric Dosage Reformulation |
6. 6.6 Industry Value Chain Analysis |
7. 6.7 Porter's Five Forces Analysis
7 Regional Market Share & Country-Level Analysis |
1. 7.1 North America | |
  1. 7.1.1 US | |
  2. 7.1.2 Canada | |
  3. 7.1.3 Mexico |
2. 7.2 Europe | |
  1. 7.2.1 Germany | |
  2. 7.2.2 UK | |
  3. 7.2.3 France | |
  4. 7.2.4 Italy | |
  5. 7.2.5 Spain | |
  6. 7.2.6 Nordic Countries | |
  7. 7.2.7 Russia | |
  8. 7.2.8 Rest of Europe |
3. 7.3 Asia-Pacific | |
  1. 7.3.1 China | |
  2. 7.3.2 India | |
  3. 7.3.3 Japan | |
  4. 7.3.4 South Korea | |
  5. 7.3.5 ASEAN | |
  6. 7.3.6 Rest of Asia-Pacific |
4. 7.4 South America | |
  1. 7.4.1 Brazil | |
  2. 7.4.2 Argentina | |
  3. 7.4.3 Rest of South America |
5. 7.5 Middle East & Africa | |
  1. 7.5.1 Saudi Arabia | |
  2. 7.5.2 UAE | |
  3. 7.5.3 South Africa | |
  4. 7.5.4 Egypt | |
  5. 7.5.5 Rest of Middle East & Africa
8 Future Outlook (2026–2035) |
1. 8.1 Predictive Formulation and Digital Twins |
2. 8.2 Delivery Platform Convergence |
3. 8.3 Supply-Chain Regionalisation |
4. 8.4 Sustainability and Traceability Reporting
9 Market Segmentation Analysis |
1. 9.1 By Product Type | |
  1. 9.1.1 Organic Chemicals | |
  2. 9.1.2 Inorganic Chemicals |
2. 9.2 By Functionality | |
  1. 9.2.1 Fillers & Diluents | |
  2. 9.2.2 Binders | |
  3. 9.2.3 Coatings | |
  4. 9.2.4 Disintegrants | |
  5. 9.2.5 Lubricants & Glidants | |
  6. 9.2.6 Suspending & Viscosity Agents | |
  7. 9.2.7 Sustained-Release Agents | |
  8. 9.2.8 Colorants, Emulsifying Agents, Preservatives & Flavouring Agents |
3. 9.3 By Formulation | |
  1. 9.3.1 Oral Solid Dosage Forms | |
  2. 9.3.2 Oral Liquid Dosage Forms | |
  3. 9.3.3 Parenteral | |
  4. 9.3.4 Topical | |
  5. 9.3.5 Others |
4. 9.4 By Source | |
  1. 9.4.1 Plant-Based | |
  2. 9.4.2 Mineral-Based | |
  3. 9.4.3 Synthetic / Chemical | |
  4. 9.4.4 Animal-Based | |
  5. 9.4.5 Marine - based
10 Competitive Landscape |
1. 10.1 Market Concentration Analysis (2026) |
2. 10.2 Competitive Benchmarking Matrix |
3. 10.3 Company Profiles | |
  1. 10.3.1 BASF SE | |
  2. 10.3.2 Roquette Frères | |
  3. 10.3.3 Ashland Global Holdings | |
  4. 10.3.4 DuPont / IFF Pharma Solutions | |
  5. 10.3.5 Evonik Industries | |
  6. 10.3.6 Croda International | |
  7. 10.3.7 DFE Pharma | |
  8. 10.3.8 JRS Pharma | |
  9. 10.3.9 Merck KGaA | |
  10. 10.3.10 Colorcon | |
  11. 10.3.11 Lubrizol Life Science | |
  12. 10.3.12 Kerry Group
11 Recent News & Developments
12 Report Scope & Methodology
13 Detailed Sources & Citations
14 Frequently Asked Questions
15 LIST OF TABLES |
TABLE 1 Global Pharmaceutical Excipients Market Size & Forecast, by Revenue (USD Billion), 2021–2035 |
TABLE 2 Global Market — Year-over-Year Growth Analysis, 2021–2035 |
TABLE 3 Driver Impact Analysis Matrix, 2026–2035 |
TABLE 4 Restraint Impact Analysis Matrix, 2026–2035 |
TABLE 5 Global Market Size, by Region, 2021–2035 (USD Billion) |
TABLE 6 North America Market Size, by Country, 2021–2035 (USD Billion) |
TABLE 7 Europe Market Size, by Country, 2021–2035 (USD Billion) |
TABLE 8 Asia-Pacific Market Size, by Country, 2021–2035 (USD Billion) |
TABLE 9 South America Market Size, by Country, 2021–2035 (USD Billion) |
TABLE 10 Middle East & Africa Market Size, by Country, 2021–2035 (USD Billion) |
TABLE 11 Global Market Size, by Product Type, 2021–2035 (USD Billion) |
TABLE 12 Global Market Size, by Functionality, 2021–2035 (USD Billion) |
TABLE 13 Global Market Size, by Formulation, 2021–2035 (USD Billion) |
TABLE 14 Global Market Size, by Source, 2021–2035 (USD Billion) |
TABLE 15 North America Market Size, by Product Type, 2021–2035 (USD Billion) |
TABLE 16 North America Market Size, by Functionality, 2021–2035 (USD Billion) |
TABLE 17 Europe Market Size, by Formulation, 2021–2035 (USD Billion) |
TABLE 18 Europe Market Size, by Source, 2021–2035 (USD Billion) |
TABLE 19 Asia-Pacific Market Size, by Product Type, 2021–2035 (USD Billion) |
TABLE 20 Asia-Pacific Market Size, by Formulation, 2021–2035 (USD Billion) |
TABLE 21 South America Market Size, by Functionality, 2021–2035 (USD Billion) |
TABLE 22 Middle East & Africa Market Size, by Source, 2021–2035 (USD Billion) |
TABLE 23 Competitive Benchmarking Matrix, 2026 |
TABLE 24 Company Profiles — Key Players |
TABLE 25 Recent Developments & Strategic Announcements, 2023–2025 |
TABLE 26 Report Scope & Methodology Summary |
TABLE 27 Detailed Sources & Citations Index
16 LIST OF FIGURES |
FIGURE 1 Market Dynamics — Drivers, Restraints, Opportunities and Challenges |
FIGURE 2 Industry Value Chain Analysis |
FIGURE 3 Porter's Five Forces Analysis |
FIGURE 4 Global Market Size Trend, 2021–2035 (USD Billion) |
FIGURE 5 Year-over-Year Growth Trajectory, 2022–2035 (%) |
FIGURE 6 Market Share by Product Type, 2025 vs 2035 (%) |
FIGURE 7 Market Share by Functionality, 2025 (%) |
FIGURE 8 Market Value by Formulation, 2025 (USD Billion) |
FIGURE 9 CAGR Comparison by Source, 2026–2035 (%) |
FIGURE 10 Regional Market Share Distribution, 2025 (%) |
FIGURE 11 Regional CAGR Comparison, 2026–2035 (%) |
FIGURE 12 North America Country-Level Share Breakdown, 2025 (%) |
FIGURE 13 Europe Country-Level Share Breakdown, 2025 (%) |
FIGURE 14 Asia-Pacific Country-Level Share Breakdown, 2025 (%) |
FIGURE 15 Competitive Landscape — Estimated Revenue Share Bands, 2026 |
FIGURE 16 Strategic Positioning Matrix — Key Suppliers |
FIGURE 17 Regulatory Milestone Timeline, 2023–2030

Certified Researchers

Customize Report

Segmentation Quick Reference

Dimension	Sub-Segments	Dominant Segment	Fastest Growing Segment
By Product Type	Organic Chemicals; Inorganic Chemicals	Organic Chemicals	Inorganic Chemicals
By Functionality	Fillers & Diluents; Binders; Coatings; Disintegrants; Lubricants & Glidants; Suspending & Viscosity Agents; Sustained-Release Agents; Colorants; Emulsifying Agents; Preservatives; Flavouring Agents	Fillers & Diluents	Sustained-Release Agents
By Formulation	Oral Solid Dosage Forms; Oral Liquid Dosage Forms; Parenteral; Topical; Others	Oral Solid Dosage Forms	Parenteral
By Source	Plant-Based; Mineral-Based; Synthetic / Chemical; Animal-Based	Synthetic / Chemical	Plant-Based
By Geography	North America; Europe; Asia-Pacific; South America; Middle East & Africa	Europe	Asia-Pacific

Market Segmentation Overview

By Product Type

Sub-Segment	Key Trend
Organic Chemicals	Co-processed cellulosic and carbohydrate blends replacing single-component diluents
Inorganic Chemicals	Dibasic calcium phosphate substitution in moisture-sensitive and hygroscopic formulations

Chemistry choice increasingly follows process choice. Formulators moving to continuous direct compression favour organic co-processed grades with characterised tabletability, while parenteral and moisture-sensitive programmes pull inorganic volumes upward.

By Functionality

Sub-Segment	Key Trend
Fillers & Diluents	Functionality-graded lactose and MCC displacing commodity equivalents
Binders	Low-shear granulation binders reformulated for twin-screw extrusion
Coatings	Fully formulated one-step film systems replacing in-house blending
Disintegrants	Superdisintegrant use rising with orally disintegrating tablet growth.
Lubricants & Glidants	Alternatives to magnesium stearate for API compatibility
Suspending & Viscosity Agents	Cellulose gum reformulation for paediatric palatability
Sustained-Release Agents	Methacrylate and HPMCAS platforms enabling once-daily conversion
Colorants, Emulsifiers, Preservatives, Flavours	Titanium dioxide replacement and preservative-free multi-dose design

Functional categories are separating into commodity and specialty tiers. Volume sits with fillers and binders; margin and intellectual property concentrate in release-modifying polymers and coating systems.

By Formulation

Sub-Segment	Key Trend
Oral Solid Dosage Forms	Continuous manufacturing tightening input specification requirements
Oral Liquid Dosage Forms	Sugar-free and preservative-free reformulation for paediatric use
Parenteral	Ultra-low-peroxide stabilisers for protein and biosimilar products
Topical	Expanding mucoadhesive and transdermal polymer systems
Others (Inhalation, Ophthalmic, Rectal)	Carrier lactose specification tightening for dry powder inhalers

Route of administration now determines purity economics more than volume does. Parenteral and inhalation programmes consume modest tonnage yet generate outsized revenue per kilogram.

By Source

Sub-Segment	Key Trend
Plant-Based	Pea, tapioca and non-GMO cellulose adoption under clean-label mandates
Mineral-Based	Cost-stable bulk diluents retaining generic-portfolio relevance.
Synthetic / Chemical	Engineered polymers dominating controlled-release applications
Animal-Based	Gelatin holding softgel positions despite BSE/TSE scrutiny

Sourcing decisions have become disclosure decisions. Sustainability reporting obligations and supply-chain traceability requirements now influence material selection as directly as technical performance once did.

Certified Researchers

Customize Report

Customer Stories

“This is really good guys. Excellent work on a tight deadline. I will continue to use you going forward and recommend you to others. Nice job”

Noah Malgeri Co-Founder

“Thanks. It’s been a pleasure working with you, please use me as reference with any other Intel employees.”

Joseph Aguayo Sales Operations & Pricing Manager

“Thanks for sending the report it gives us a good global view of the Betaïne market.”

Peter Groot koerkamp Account and Business Manager

“Thank you, this will be very helpful for OQS.”

La Terria Dodd Program Support Specialist

“We found the report very insightful! we found your research firm very helpful. I'm sending this email to secure our future business.”

Younghwan Choi Senior Retail Manager

“I am very pleased with how market segments have been defined in a relevant way for my purposes (such as "Portable Freezers & refrigerators" and "last-mile"). In general the report is well structured. Thanks very much for your efforts.”

Mark Irwin Management Consultant

“I have been reading the first document or the study, ,the Global HVAC and FP market report 2021 till 2026. Must say, good info! I have not gone in depth at all parts, but got a good indication of the data inside!”

Rob Kooiker Group Product Manager HVAC & Fire Protection GMA

“We got the report in time, we really thank you for your support in this process. I also thank to all of your team as they did a great job.”

Akif Moroglu Strategy & Business Development Director

“The Automotive 48V ECU Components Procurement Intelligence Study” was a complex project, but the Market Research Future (MRFR) team handled it with quality, agility, and customer-centricity. They delivered all requested data on time and within the agreed scope. The team, including Shubhendra Anand and Rahul Gotadki, was always readily available to clarify questions and swiftly implement necessary adjustments, driving the project to a successful conclusion within a very demanding timeframe.
I would also like to specifically commend Akshay Agarwal for his responsiveness and support at every stage—from our initial inquiry on May 6th through to final delivery on June 18th. His dedication made the entire process seamless.”